Effects of Water and Glucose Drinks on Cardiovascular Function in Subjects With and Without Postprandial Hypotension

March 15, 2016 updated by: Karen Jones, Royal Adelaide Hospital

Cardiovascular Function and Postprandial Hypotension (PPH): Effect of an Oral Glucose Load on Cardiac Contractility, Cardiac Output, Diastolic Function and Endothelial Function - Relationship to Gastric Emptying

To determine whether the changes in blood pressure (BP) which occur following meals in normal people and patients who have substantial falls in BP after a meal postprandial hypotension (PPH)) are associated with changes in cardiac function. Eligible subjects who have been previously diagnosed with PPH will report to the Queen Elizabeth Hospital, on two occasions, following an overnight fast. Subjects will be cannulated and have a BP cuff placed around their upper arm. Following this, subjects will ingest either a drink containing 75 grams of glucose and 150mg of a C13 Acetate (which is metabolised and excreted in the breath, enabling noninvasive measurements of gastric emptying), made up to 300mL water, or on the other study day, 300mL water alone. The order of the study days will be randomised. Following the drink, for 3 hours, measurements will be taken at regular intervals of BP, heart rate, breath samples (on the study day with the Acetate only), blood samples (for measurement of blood glucose and gut hormones) and transthoracic echocardiography (TTE) (for assessment of end systolic and diastolic cardiac volume, cardiac output, cardiac contractility and diastolic function). After the 3 hours of measurements, the cannula will be removed and subjects will be offered lunch prior to leaving the department. Following lunch, on one study day, subjects will have their autonomic nerve function tested noninvasively, using an ECG.

Study Overview

Detailed Description

Subjects who meet the inclusion criteria will be required to attend the Queen Elizabeth Hospital, on two separate occasions, at 08:30h following an overnight fast (solids for 14 hours and liquids for 12 hours) and abstaining from smoking for 12 hours prior to the study day. The order of the study days will be randomized using the online Random Integer Set Generator program (RANDOM.ORG).

On each of the study days, subjects will be seated and have an intravenous cannula inserted into an antecubital vein in the arm for blood sampling and an automated blood pressure (BP) cuff (DINAMAP ProCare 100, GE Medical Systems, Milwaukee, WI, USA) placed around the opposite arm for measurements of BP (systolic and diastolic) and heart rate (HR).

After a 15-minute rest period, subjects will consume a drink consisting of either 75g glucose and 150 mg of 13C-acetate made up to 300 ml with water, or 300 ml water, within 3 minutes (t = -3 - 0 minutes).

BP and HR will be measured at 3 minute intervals during the 30-minute rest period prior to the drink (i.e. t = -30 - 0 minutes) and at 3 minute intervals from t = 0 - 180 minutes.

Blood samples (~ 18ml) will be taken prior (t = -3 minutes) to the drink and then at t = 30, 60, 90, 120 and 180 minutes for the subsequent measurement of blood glucose, serum insulin and incretin hormones. Samples will be stored at -70°C until analysed. Blood glucose will be determined immediately using a portable glucometer (Medisense Companion 2 meter, Medisense Inc, Waltham, USA).

Following the 75g drink consisting of 75g glucose and 150 mg of 13C-acetate made up to 300 ml with water, at t = -3 minutes, and every 5 minutes between t = 0 - 60, followed by every 15 minutes between t = 60 - 180, breath samples will be collected in sealed tubes for subsequent analysis of 13CO2 for measurement of gastric emptying.

At t = -30 minutes and then at t = 30, 60, 90, 120 and 180 minutes, subjects will also undergo Transthoracic Echocardiogram (TTE) for assessment of (i) end-systolic and diastolic volumes (ii) cardiac output (iii) cardiac contractility, as assessed by measuring

  1. left ventricular dP/dt and
  2. overall wall motion by Doppler tissue imaging (DTI) of basal mitochondrial segments (iv) diastolic function, as assessed by measuring

a) mitral inflow velocities b) DTI of mitral annulus c) left atrial size and d) pulmonary vein flow patterns Prior to each measurement, subjects will be allowed to rest for 15 minutes, remaining still in a supine position.

At t = 180 the cannulae will be removed and subjects will be offered a light lunch before leaving the department. The total amount of blood collected during the two visits is ~180 ml.

On one of the study days after completion of these measurements autonomic nerve function will be assessed using standardised cardiovascular reflex tests. Parasympathetic function will be calculated by the variation (R - R interval) of the HR during deep breathing and the immediate HR response to standing ("30:15" ratio). Sympathetic function will be assessed by the fall in systolic BP in response to standing.

Study Type

Interventional

Enrollment (Actual)

8

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years to 85 years (Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Control subjects: subjects from this group will be healthy, with normal BMI. PPH subjects: Patients who have been diagnosed with PPH (defined as a fall in systolic blood pressure (BP) of > 20mmHg within 2 hours of a meal).

Exclusion Criteria:

  • No history of severe respiratory, cardiovascular, hepatic and/or renal disease, diabetes, are not taking any medication with effects on blood pressure or gastrointestinal function, have not donated blood for the past 12 weeks or been involved in any research projects for the past 3 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Glucose
75g glucose and 150mg C13-acetate in 300ml water
75g glucose and 150 mg of 13C-acetate made up to 300 ml with water
Placebo Comparator: Control
300ml water
300ml water

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline systolic blood pressure over time.
Time Frame: time= 0 - 120 min
time= 0 min is defined as the consumption of either the experimental or control drink, i.e. outcome will be assessed for 2 hours.
time= 0 - 120 min

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline cardiac output as assessed by echocardiography, over time.
Time Frame: time= 0 - 120 min
time= 0 min is defined as the consumption of either the experimental or control drink, i.e. outcome will be assessed for 2 hours.
time= 0 - 120 min
Change from baseline stroke volume as assessed by echocardiography, over time.
Time Frame: time= 0 - 120 min
time= 0 min is defined as the consumption of either the experimental or control drink, i.e. outcome will be assessed for 2 hours.
time= 0 - 120 min
Change from baseline ejection fraction as assessed by echocardiography, over time.
Time Frame: time= 0 - 120 min
time= 0 min is defined as the consumption of either the experimental or control drink, i.e. outcome will be assessed for 2 hours.
time= 0 - 120 min

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Karen L Jones, PhD, karen.jones@adelaide.edu.au

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2013

Primary Completion (Actual)

October 1, 2014

Study Completion (Actual)

October 1, 2014

Study Registration Dates

First Submitted

March 6, 2016

First Submitted That Met QC Criteria

March 15, 2016

First Posted (Estimate)

March 18, 2016

Study Record Updates

Last Update Posted (Estimate)

March 18, 2016

Last Update Submitted That Met QC Criteria

March 15, 2016

Last Verified

March 1, 2016

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymous study data (minus all demographic data which compromises confidentiality) will be made available in a publicly accessible depository after publication.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Autonomic Nervous System Diseases

Clinical Trials on Glucose

Subscribe